WINTON GROUP Ltd Takes $3.36 Million Position in Royalty Pharma PLC $RPRX

WINTON GROUP Ltd purchased a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 95,200 shares of the biopharmaceutical company’s stock, valued at approximately $3,359,000.

Several other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Royalty Pharma in the second quarter worth $181,388,000. Arrowstreet Capital Limited Partnership raised its position in shares of Royalty Pharma by 118.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,976,480 shares of the biopharmaceutical company’s stock worth $107,243,000 after buying an additional 1,615,706 shares in the last quarter. Amundi raised its holdings in Royalty Pharma by 126.1% during the second quarter. Amundi now owns 2,797,471 shares of the biopharmaceutical company’s stock worth $101,240,000 after purchasing an additional 1,560,093 shares in the last quarter. Jupiter Asset Management Ltd. raised its stake in shares of Royalty Pharma by 126.5% in the 2nd quarter. Jupiter Asset Management Ltd. now owns 2,470,706 shares of the biopharmaceutical company’s stock worth $89,020,000 after buying an additional 1,380,115 shares in the last quarter. Finally, State Street Corp lifted its holdings in Royalty Pharma by 7.1% in the 2nd quarter. State Street Corp now owns 10,194,938 shares of the biopharmaceutical company’s stock valued at $367,324,000 after acquiring an additional 678,810 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Leerink Partners set a $45.00 target price on shares of Royalty Pharma in a research report on Thursday, December 11th. UBS Group upgraded shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target on the stock in a report on Friday, January 30th. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $48.67.

Royalty Pharma Stock Performance

RPRX stock opened at $45.97 on Wednesday. The firm has a 50 day simple moving average of $42.81 and a 200 day simple moving average of $39.37. Royalty Pharma PLC has a 52 week low of $29.66 and a 52 week high of $47.86. The stock has a market cap of $26.52 billion, a P/E ratio of 34.05 and a beta of 0.40. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The firm had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. Research analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Friday, February 20th were issued a dividend of $0.235 per share. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a dividend yield of 2.0%. The ex-dividend date was Friday, February 20th. Royalty Pharma’s dividend payout ratio is 69.63%.

Insiders Place Their Bets

In related news, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $46.78, for a total transaction of $1,627,522.98. Following the completion of the sale, the chief financial officer owned 45,761 shares of the company’s stock, valued at approximately $2,140,699.58. This trade represents a 43.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 737,078 shares of company stock valued at $29,862,002. Insiders own 18.90% of the company’s stock.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.